PEPG — PepGen Inc. - Common Stock
Session close: $4.61. Regular-session share volume: 66,623,608. Change from previous close: +92.89%.
Key developments
Coverage framed the data as competitive pressure on rivals in the indication, noting a competitor is nearing completion of a pivotal trial while another recently reported a late-stage failure. Patient-reported outcomes were described as inconclusive, with favorable directional trends on one scale and mixed results on another.
Company news PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure. · Company news PepGen Stock Doubles in One Session - Here's Why
News sources
Company news PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure. · Company news PepGen Stock Doubles in One Session - Here's Why · Company news PepGen Stock Doubles in One Session - Here's Why · Company news PepGen stock soars over 100% on positive Phase 2 trial data for DM1 drug · Company news PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights · Company news PepGen Q3 EPS $(0.28) Misses $(0.27) Estimate · Company news PepGen Announces Data From Its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 Demonstrates Mean Splicing Correction Of 46.5%; PGN-EDODM1 Showed High Tolerance; · Company news PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights · Company news PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures · Market context — Mentions PEPG in the article text. 12 Health Care Stocks Moving In Tuesday's Intraday Session · Market context — Mentions PEPG in the article text. Nasdaq Down Over 200 Points; US Consumer Prices Increase 0.4% In October · Company mentioned — Mentions PEPG in the article text. Gold Down 2%; TransDigm Group Posts Upbeat Earnings